Cancer disease remains one of the most cause of death worldwide. The
drawbacks that were associated to the chemotherapy treatments are impetus
for finding more efficacious, and better tolerated new drugs. This study was
conducted to optimize the low doses of cisplatin (Cis) antitumor effect by the
co-treatment of ethylenediamine tetra acetic acid (EDTA) in EAC-bearing
mice. Sixty-four female CD-1 mice were divided into eight groups (n = 8) as
follows: Gp1 was a negative control. Gp2 had inoculated with 1×106 EACcells/mouse interperitoneally (i.p.). Gp3, Gp4 and Gp5 had inoculated with
the same number of EAC-cells as in Gp2, then injected with 0.125, 0.250 or
0.5 mg/Kg of Cis i.p, respectively. Gp6, Gp7 and Gp8 had inoculated with
EAC-cells as in Gp2, then injected with the low doses of Cis as in Gp3- G5
in combination with EDTA (50 mg/Kg), respectively. At day 14, all groups
were bled to collect sera for biochemical assessments. The tumor ascites was
collected for determining the total tumor volume and total tumor counts.
Liver tissues were harvested for histopathological investigations. The results
showed that co-treatment of EDTA (50 mg/Kg) along with the low doses of
Cis (0.125, 0.25 or 50 mg/Kg) led to significant reduction in tumor volume,
tumor cells count, improved the liver, kidney functions, and antioxidant
status. Among all the treated EAC-bearing mice groups, mice that had a
combined treatment with Cis (0.5 mg/Kg) and EDTA (50 mg/Kg) showed
the highest antitumor effect with highly improvements in the liver functions
and architectures.